Stanford University (Global Rights to Novel VT-109) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Stanford University (Global Rights to Novel VT-109) General Information

Description

Global rights of the novel next-generation fusion protein targeting BAFF and APRIL.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Stanford University (Global Rights to Novel VT-109) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Stanford University (Global Rights to Novel VT-109)‘s full profile, request access.

Request a free trial

Stanford University (Global Rights to Novel VT-109) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Stanford University (Global Rights to Novel VT-109)‘s full profile, request access.

Request a free trial

Stanford University (Global Rights to Novel VT-109) FAQs

  • Where is Stanford University (Global Rights to Novel VT-109) headquartered?

    Stanford University (Global Rights to Novel VT-109) is headquartered in .

  • What industry is Stanford University (Global Rights to Novel VT-109) in?

    Stanford University (Global Rights to Novel VT-109)’s primary industry is Buildings and Property.

  • Is Stanford University (Global Rights to Novel VT-109) a private or public company?

    Stanford University (Global Rights to Novel VT-109) is a Private company.

  • What is the current valuation of Stanford University (Global Rights to Novel VT-109)?

    The current valuation of Stanford University (Global Rights to Novel VT-109) is .

  • What is Stanford University (Global Rights to Novel VT-109)’s current revenue?

    The current revenue for Stanford University (Global Rights to Novel VT-109) is .

  • Who are Stanford University (Global Rights to Novel VT-109)’s investors?

    Stanford University has invested in Stanford University (Global Rights to Novel VT-109).

  • When was Stanford University (Global Rights to Novel VT-109) acquired?

    Stanford University (Global Rights to Novel VT-109) was acquired on 13-Jan-2025.

  • Who acquired Stanford University (Global Rights to Novel VT-109)?

    Stanford University (Global Rights to Novel VT-109) was acquired by Vera Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process